Recycled oil transformer pioneer Hydrodec reports its ‘SuperfineTM’ product has completed independent quality assurance verification.
The AIM-quoted company, chaired by innovative product entrepreneur and former City magnate John Gunn, says samples of ‘Superfine’ have been sent to its customers ‘for their final approval’. According to Gunn, this initial verification ‘signifies commencement of full commercial operation’ of London-based Hydrodec’s US facility in Canton, Ohio, with customer deliveries ‘in the immediate future’.
Floated at 5p four years ago and last recommended by Growth Company Investor at 26p last year, Hydrodec shares now trade at 45p, valuing the company at £120.95 million. Some profit taking might be prudent, but there could be more growth to come.
Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.
Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. You can purchase the directory at the pre-order price with a 15% saving (+VAT). Offer valid until 15th September 2015. Order your copy today.
The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info
Latest small-cap and growth company news
Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.
Technological innovations have seriously helped reshape the way in which we interact with the world and the people around us. And the smartphone has become a one-stop device for communication, travel, online browsing, taking photos, watching videos and even high-definition gaming.
Shares in clinical research organisation Venn Life Sciences are up around 5 per cent at the time of writing following the company's positive trading update ahead of its results announcement for the first half of the year on 22 September.